MSI OncoKitDx: The Pinnacle of Microsatellite Instability Analysis

Understanding the intricacies of cancer demands a level of diagnostic accuracy that leaves no room for error. MSI OncoKitDx by Health in Code combines state-of-the-art conventional PCR and capillary electrophoresis to offer a comprehensive and reliable analysis of microsatellite instability (MSI), a pivotal marker for various cancer types.

At the core of the MSI OncoKitDx lies its multi-marker panel, designed to flawlessly detect instability in both tumoral and healthy tissue. Featuring eight markers—including the renowned Bethesda Panel recommended by the National Cancer Institute since 1997—this kit offers a diagnostic depth that’s second to none.

Just like how each cancer patient is unique, so is each tissue sample. That’s why the MSI OncoKitDx can simultaneously analyze multiple markers, giving clinicians a more holistic picture of the disease state, enhancing prognosis, and even tailoring treatment approaches. This adaptability makes it an invaluable asset in personalized medicine, guiding therapeutic decisions that are custom-fit to each patient’s unique genetic landscape.

Tailored Features for Robust Analysis
– Multi-Marker Panel: 8 unique markers for comprehensive MSI analysis.
– Bethesda Inclusion: 5 Bethesda Panel markers for added reliability.
– Capillary Electrophoresis: Advanced detection method for refined analysis.
– Multi-Tissue Compatibility: Valid for a variety of tissue types.
– Amplification Range: A versatile 90-200 bp range.
– Quality Control: Includes a genomic DNA control for optimal results.

We understand that in the field of cancer diagnostics, there’s no compromise on quality. That’s why the MSI OncoKitDx is ISO 13485:2018 certified, ensuring its alignment with the highest standards of quality and reliability.

Conclusion: Setting a New Standard in Cancer Care
The MSI OncoKitDx offers a new dimension in cancer diagnostics, promising a future where every diagnosis is not just accurate but also timely and comprehensive. For clinicians and laboratories seeking to push the boundaries of what’s possible in cancer care, your next breakthrough is here.